<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="430">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05155553</url>
  </required_header>
  <id_info>
    <org_study_id>SMF-DHF-18-0489-002</org_study_id>
    <nct_id>NCT05155553</nct_id>
  </id_info>
  <brief_title>QIAstat-Dx® Meningitis/Encephalitis Panel Performance Evaluation Study</brief_title>
  <official_title>An Observational Clinical Performance Evaluation Study Testing Residual Specimens of Cerebrospinal Fluid Obtained by Lumbar Puncture From Meningitis/Encephalitis Subjects Using the QIAstat-Dx® Meningitis/Encephalitis Panel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QIAGEN Gaithersburg, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>QIAGEN Gaithersburg, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study for performance evaluation of the QIAstat-Dx® Meningitis/Encephalitis Panel in&#xD;
      comparison with other chosen comparator methods.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter study aims to evaluate the performance of QIAstat-Dx Meningitis/Encephalitis&#xD;
      (ME) Panel with another validated comparator method.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 3, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PPA</measure>
    <time_frame>6 months</time_frame>
    <description>positive percentage agreement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NPA</measure>
    <time_frame>6 months</time_frame>
    <description>negative percentage agreement</description>
  </primary_outcome>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Meningitis/Encephalitis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>QIAstat-Dx® Meningitis/Encephalitis (ME) Panel</intervention_name>
    <description>The performance of QIAstat-Dx® Meningitis/Encephalitis Panel will be evaluated in comparison with another validated comparator method, followed by bidirectional sequencing using residual specimens of cerebrospinal fluid (CSF) obtained by lumbar puncture from subjects with signs and symptoms of meningitis and/or encephalitis.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      residual specimens of CSF obtained by lumbar puncture&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects (adults and children) with signs and symptoms of meningitis and/or encephalitis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Residual specimens (minimum 500μL) of CSF obtained by lumbar puncture from subjects&#xD;
             with signs and symptoms of meningitis and/or encephalitis following completion of&#xD;
             routine testing Specimen that have not undergone more than 3 freeze/thaw cycles.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Specimens not fitting criteria outlined above.&#xD;
&#xD;
          -  CSF obtained from an external ventricular drain or shunt source.&#xD;
&#xD;
          -  Lack of clear subject identification or label on residual banked CSF specimen.&#xD;
&#xD;
          -  Specimen has been centrifuged.&#xD;
&#xD;
          -  Obvious physical damage of banked residual specimen.&#xD;
&#xD;
          -  Repeat specimens from the same subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Johnson</last_name>
    <role>Study Director</role>
    <affiliation>QIAGEN Gaithersburg, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Qiagen</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 9, 2021</study_first_submitted>
  <study_first_submitted_qc>December 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2021</study_first_posted>
  <last_update_submitted>December 9, 2021</last_update_submitted>
  <last_update_submitted_qc>December 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>all samples are residual and anonymized</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

